Matrix metalloproteinases (MMPs): Modern molecular markers of open-angle glaucoma diagnosis and therapy;Metaloproteinazy macierzowe (MMPs)-nowoczesne markery molekularne do prognozowania i terapii jaskry otwartego kąta

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 582-592

  Kowalski, Michał ^a   Walczak, Anna ^b   Majsterek, Ireneusz ^b,c  

^a Niepubliczny Zakład Opieki Zdrowotnej Sal Med Łódź ^*  (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Glaucoma; Marker; Matrix metalloproteinases

Indexed keywords

BIOLOGICAL MARKER; MATRIX METALLOPROTEINASE;

ENZYMOLOGY; HUMAN; METABOLISM; OPEN ANGLE GLAUCOMA; REVIEW;

BIOLOGICAL MARKERS; GLAUCOMA, OPEN-ANGLE; HUMANS; MATRIX METALLOPROTEINASES;

EID: 60649111174     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Agapova O.A., Kaufman P.L., Lucarelli M.J., Gabelt B.T., Hernandez M.R.: Differential expression of matrix metalloproteinases in monkey eyes with experimental glaucoma or optic nerve transection. Brain Res., 2003; 967: 132-143
2. Ahonenm M., Poukkula M., Baker A.H., Kashiwagi M., Nagase H., Eriksson J.E., Kähäri V.M.: Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene, 2003; 22: 2121-2134
3. Arenas I.A., Xu Y., Lopez-Jaramillo P., Davidge S.T.: Angiotensin IIinduced MMP-2 release from endothelial cells is mediated by TNF-α. Am. J. Physiol. Cell Physiol., 2004; 286: C779-C784
4. Bazan N.: COX-2 as a multifunctional neuronal modulator. Nat. Med., 2001; 7: 414-415
5. Bian J., Wang Y., Smith M.R., Kim H., Jacobs C., Jackman J., Kung H., Colburn N.H., Sun Y.: Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis, 1996; 17: 1805-1811
6. Bruner-Tran K.L., Eisenberg E., Yeaman G.R., Anderson T.A., McBean J., Osteen K.G.: Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice. J. Clin. Endocrinol. Metab., 2002; 87: 4782-4791
7. Chesler L., Golde D.W., Bersch N., Johnson M.D.: Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-l. Blood, 1995; 86: 4506-4515
8. CioffiG.A.: Ischemic model of optic nerve injury. Trans. Am. Ophthalmol. Soc., 2005; 103: 592-613
9. Cordeiro M., Guo L., Luong V., Harding G., Wang W., Jones H., Moss S., Sillito A., Fitzke F.: Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc. Natl. Acad. Sci. USA, 2004; 101: 13352-13356
10. Curry T.E.Jr, Osteen K.G.: The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr. Rev., 2003; 24: 428-465
11. Damsky C., Sutherland A., Fisher S.: Extracellular matrix 5: Adhesive interactions in early mammalian embryogenesis, implantation, and placentation. FASEB J., 1993; 7: 1320-1329
12. Di Girolamo N., Coroneo M. T., Wakefield D.: Active matrilysin (MMP-7) in human pterygia: potential role in angiogenesis. Invest. Ophthalmol. Vis. Sci., 2001; 42: 1963-1968
13. Duffy M.J., Maguire T.M., Hill A., McDermott E., O'Higgins N.: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res., 2000; 2: 252-257
14. Dziankowska-Bartkowiak B., Ebrowska A., Joss-Wichman E., Kobos J., Waszczykowska E.: Stêenie metaloproteinazy 2 i 9 (MMP-2 i MMP-9) w surowicy chorych na twardzinê ukadow-porównanie z ich ekspresj w chorobowo zmienionej skórze-badania wstêpne. Post. Dermatol. Alergol., 2007; 2: 73-81
15. Entrez Gene TIMP1 TIMP metallopeptidase inhibitor 1 [Homo sapiens]. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDeta ilView&TermToSearch=7076&ordinalpos=12&itool=EntrezSystem2 .PEntrez.Gene.Gene-ResultsPanel.Gene-RVDocSum (19-04.2008)
16. Entrez Gene TIMP2 TIMP metallopeptidase inhibitor 2 [Homo sapiens]. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDeta ilView&TermToSearch=7077&ordinalpos=11&itool=EntrezSystem2 .PEntrez.Gene.Gene-ResultsPanel.Gene-RVDocSum (19-04.2008)
17. Entrez Gene TIMP3 TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory) [Homo sapiens]. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&T ermToSearch=7078&ordinalpos=8&itool=EntrezSystem2.PEntrez. Gene.Gene-ResultsPanel.Gene-RVDocSum (19-04.2008)
18. Entrez Gene TIMP4 TIMP metallopeptidase inhibitor 4 [Homo sapiens]. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDeta ilView&TermToSearch=7079&ordinalpos=1&itool=EntrezSystem2. PEntrez.Gene.Gene-ResultsPanel.Gene-RVDocSum (19-04.2008)
19. Feldman A.L., Stetler-Stevenson W.G., Costouros N.G., Knezevic V., Baibakov G., Alexander H.R. Jr, Lorang D., Hewitt S.M., Seo D., Miller M.S., O'Connor S., Libutti S.K.: Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism. Cancer Res., 2004; 64: 4481-4486
20. Fontaine V., Jacob M.P., Houard X., Rossignol P., Plissonnier D., Angles-Cano E., Michel J.B.: Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am. J. Pathol., 2002; 161: 1701-1710
21. Foster P.J.: Advances in the understanding of primary angle-closure as a cause of glaucomatous optic neuropathy. Community Eye Health, 2001; 14: 37-39
22. Foster P.J., Buhrmann R., Quigley H.A., Johnson G.J.: The definition and classification of glaucoma in prevalence surveys. Br. J. Ophthalmol., 2002; 86: 238-242
23. Fuchsjager-Mayrl G., Wally B., Georgopoulos M., Rainer G., Kircher K., Buehl W., Amoako-Mensah T., Eichler H., Vass C., Schmetterer L.: Ocular blood flow and systemic blood pressure in patients with primary open glaucoma and ocular hypertension. Invest. Ophthalmol. Vis. Sci., 2004; 45: 834-839
24. Goda S., Inoue H., Umehara H., Miyaji M., Nagano Y., Harakawa N., Imai H., Lee P., MaCarthy J.B., Ikeo T., Domae N., Shimizu Y., Iida J.: Matrix metalloproteinase-1 produced by human CXCL12-stimulated natural killer cells. Am. J. Pathol., 2006; 169: 445-458
25. Golubnitschaja O., Yeghiazaryan K., Liu R., Monkemann H., Leppert D., Schild H., Haefliger I.O., Flammer J.: Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J. Glaucoma, 2004; 13: 66-72
26. Guo L., Moss S.E., Alexander R.A., Ali R.R., Fitzke F.W., Cordeiro M.F.: Retinal ganglion cell apoptosis in glaucoma Is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest. Ophthalmol. Vis. Sci., 2005; 46: 175-182
27. Gutteridge I.F.: Normal tension glaucoma: diagnostic features and comparisons with primary open angle glaucoma. Clin. Exp. Optom., 2000; 83: 161-172
28. Herman M.P., Sukhova G.K., Kisiel W., Foster D., Kehry M.R., Libby P., Schonbeck U.: Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J. Clin. Invest., 2001; 107: 1117-1126
29. Higashi S., Miyazaki K.: Identification of a region of β-amyloid precursor protein essential for its gelatinase A inhibitory activity. J. Biol. Chem., 2003; 278: 14020-14028
30. Ho S.L., Dogar G.F., Wang J., Crean J., Wu Q.D., Oliver N., Weitz S., Murray A., Cleary P.E., O'Brien C.: Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. Br. J. Ophthalmol., 2005; 89: 169-173
31. Hollander D.A., Sarfarazi A., Stoilov I., Wood I.S., Fredrick D.R, Alvarado J.A.: Genotype and phenotype correlations in congenital glaucoma. Trans. Am. Ophthalmol. Soc., 2006; 104: 183-195
32. Holmbeck K., Bianco P., Pidoux I., Inoue S., Billinghurst R. C., Wu W., Chrysovergis K., Yamada S., Birkedal-Hansen H., Poole A.R.: The metalloproteinase MT1-MMP is required for normal development and maintenance of osteocyte processes in bone. J. Cell Sci., 2005; 118: 147-156
33. Hsu J.Y., McKeon R., Goussev S., Werb Z., Lee J.U., Trivedi A., Noble-Haeusslein L.J.: Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J. Neurosci., 2006; 26: 9841-9850
34. Hyams S.W, Keroub C., Pokotilo E.: Mixed glaucoma. Br. J. Ophthalmol., 1977; 61: 105-106
35. Ito T., Ohguro H., Mamiya K., Ohguro I., Nakazawa M.: Effects of antiglaucoma drops on MMP and TIMP balance in conjunctival and subconjunctival tissue. Invest. Ophthalmol. Vis. Sci., 2006; 47: 823-830
36. Kazes I., Elalamy I., Sraer J., Hatmi M., Nguyen G.: Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood, 2000; 96: 3064-3069
37. Ko M.K., Kim D.S., Ahn Y.K.: Peripapillary circle of Zinn-Haller revealed by fundus fluorescein angiography. Br. J. Ophthalmol., 1997; 82: 663-667
38. Koliakos G.G., Konstas A.G., Schlotzer-Schrehardt U., Hollo G., Mitova D., Kovatchev D., Maloutas S., Georgiadis N.: Endothelin-1 concentration is increased in the aqueous humour of patients with exfoliation syndrome. Br. J. Ophthalmol., 2004; 88: 523-527
39. Krajewska M.: Nowoczesne badania diagnostyczne w jaskrze. Przew. Lek., 2002; 5: 99-101
40. Lambert E., Boudot C., Kadri Z., Soula-Rothhut M., Sowa M., Mayeux P., Hornebeck W., Haye B., Petitfrere E.: Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem. J., 2003; 372: 767-774
41. Lee C., Lin C., Lin W., Liang K., Luo S., Wu C., Wang S., Yang C.: TNF-A induces MMP-9 expression via activation of Src/EGFR, PDGFR/PI3K/Akt cascade and promotion of NF-κB/p300 binding in human tracheal smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol., 2007; 292: 799-812
42. Lee K.S., Min K.H., Kim S.R., Park S.J., Park H.S., Jin G.Y., Lee Y.C.: Vascular endothelial growth factor modulates matrix metalloproteinase-9 expression in asthma. Am. J. Respir. Crit. Care Med., 2006; 174: 161-170
43. Levkau B., Kenagy R.D., Karsan A., Weitkamp B., Clowes A.W., Ross R., Raines E.W.: Activation of metalloproteinases and their association with integrins: an auxiliary apoptotic pathway in human endothelial cells. Cell Death Differ., 2002; 9: 1360-1367
44. Lipka D., Boraty.ski J.: Metaloproteinazy MMP. Struktura i funkcja. Post. Hig. Med. Do.w., 2008; 62: 328-336
45. Liu C.J., Huang Y.L., Ju J.P., Lu C.L., Chiu A.W.: Altered transcripts expression of matrix metalloproteinases and their tissue inhibitors in tenon capsule of patients with glaucoma. J. Glaucoma., 2004; 13: 486-491
46. Liu L., Chang H., Chiang L., Hung W.: Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res., 2003; 63: 3069-3072
47. ukaszewicz M., Mroczko B., Szmitkowski M.: Rola metaloproteinaz i ich inhibitorow w raku trzustki. Post. Hig. Med. Do.w., 2008; 62: 141-147
48. Martina D.C., Fowlkesb J.L., Babica B., Khokhaa R.: insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J. Cell Biol., 1999; 146: 881-892
49. Mengshol J.A., Vincenti M.P., Brinckerhoff C.E.: IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucl. Acids Res. 2001; 29: 4361-4372
50. Morgan J., Caprioli J., Koseki Y.: Nitric oxide mediates excitotoxic and anoxic damage in rat retinal ganglion cells cocultured with astroglia. Arch. Ophthalmol., 1999; 117: 1524-1529
51. Mott J.D., Thomas C.L., Rosenbach M.T., Takahara K., Greenspan D.S., Banda M.J.: Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. Biol. Chem. 2000; 275: 1384-1390
52. Murphy A.N., Unsworth E.J., Stetler-Stevenson W.G.: Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell Physiol., 1993; 157: 351-358
53. Nagase H., Visse R., Murphy G.: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res., 2006; 69: 562-573
54. Neufeld A.H., Sawada A., Becker B.: Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc. Natl. Acad. Sci. USA, 1999; 96: 9944-9948
55. Newby A.C.: Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev., 2005; 85: 1-31
56. Nizankowska M.H., Kaczmarek R.: Prevalence of glaucoma in the Wroclaw population. The Wroclaw epidemiological study. Ophthalmic. Epidemiol., 2005; 12: 363-371
57. Noske W., Hensen J., Wiederholt M.: Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract. Graefes Arch. Clin. Exp. Ophthalmol.. 1997; 235: 551-552
58. Nunez O., Fernandez-Martinez A., Majano P.L., Apolinario A., Gomez-Gonzalo M., Benedicto I., Lopez-Cabrera M., Bosca L., Clemente G., Garcia-Monzon C., Martin-Sanz P.: Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut, 2004; 53: 1665-1672
59. Oelmann E., Herbst H., Zuhlsdorf M., Albrecht O., Nolte A., Schmitmann C., Manzke O., Diehl V., Stein H., Berdel W.E.: Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells. Blood, 2002; 99: 258-267
60. Olewicz-Gawlik A., Hrycaj P., cki J.K.: Metaloproteinazy w patogenezie zapalnych ukadowych chorób reumatycznych. Reumatologia, 2005; 43: 280-285
61. Pease M.E., McKinnon S.J., Quigley H.A., Kerrigan-Baumrind L.A., Zack D.J.: Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest. Ophthalmol. Vis. Sci., 2000; 41: 764-774
62. Porter S., Clark I.M., Kevorkian L., Edwards D.R.: The ADAMTS metalloproteinases. Biochem. J., 2005; 386: 15-27
63. Quigley H.A., Addicks E.M.: Chronic experimental glaucoma in primates. II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport. Invest. Ophthalmol. Vis. Sci., 1980; 19: 137-152
64. Ra H., Parks W.C.: Control of matrix metalloproteinase catalytic activity. Matrix Biol., 2007; 26: 587-596
65. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D.L., Quigley J.P.: Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem., 1999; 274: 13066-13076
66. Resnikoff S., Pascolini D., Etya'ale D., Kocur I., Pararajasegaram R., Pokharel G.P., Mariotti S.P.: Global data on visual impairment in the year 2002. Bull. World Health Organ., 2004; 82: 844-851
67. Ricke W.A., Smith G.W., Smith M.F.: Matrix metalloproteinase expression and activity following prostaglandin F2a-induced luteolysis. Biol. Reprod., 2002; 66: 685-691
68. Rönkkö S., Rekonen P., Kaarniranta K., Puustjärvi T., Teräsvirta M., Uusitalo H.: Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma. Graefes Arch. Clin. Exp. Ophthalmol., 2007; 245: 697-704
69. Schlötzer-Schrehardt U., Lommatzsch J., Küchle M., Konstas A.G., Naumann G.O.: Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci., 2003; 44: 1117-1125
70. Sternlicht M.D, Werb Z.: How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Biol., 2001; 17: 463-516
71. Stetler-Stevenson W.G., Bersch N., Golde D.W.: Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett., 1992; 296: 231-234
72. Szaflik J., Izdebska I., Tesla P.: Jaskra. Przew. Lek., 2000; 3: 88-96
73. liwowska I., Kopczyñski Z.: Metaloproteinazy macierzy zewntrzkomórkowej-charakterystyka biochemiczna i kliniczna wartoæ oznaczania u chorych na raka piersi. Wspó. Onkol., 2005; 9: 327-335
74. Tamm E.R., Fuchshofer R.: What increases outflow resistance in primary open-angle glaucoma? Surv. Ophthalmol., 2007; 52: S101-S104
75. Taraboletti G., D'Ascenzo S., Borsotti P., Giavazzi R., Pavan A., Dolo V.: Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am. J. Pathol., 2002; 160: 673-680
76. Taylor C., Senchyna M., Flanagan J., Joyce E., Cliche D.O., Boone A.N., Culp-Stewart S., Thompson J.E.: Role of eIF5A in TNF-A-mediated apoptosis of lamina cribrosa cells. Invest. Ophthalmol. Vis. Sci., 2004; 45: 3568-3576
77. Tchetverikov I., Ronday H.K., van El B.,. Kiers G.H, Verzijl N., TeKoppele J.M., Huizinga T.W., DeGroot J., Hanemaaijer R.: MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann. Rheum. Dis., 2004; 63: 881-883
78. Thomas-Ecker S., Lindecke A., Hatzmann W., Kaltschmidt C., Zänker K.S., Dittmar T.: Alteration in the gene expression pattern of primary monocytes after adhesion to endothelial cells. Proc. Natl. Acad. Sci. USA, 2007; 104: 5539-5544
79. Verstappen J., Von den Hoff J.W.: Tissue inhibitors of metalloproteinases (TIMPs): their biological functions and involvement in oral disease. J. Dent. Res., 2006; 85: 1074-1084
80. Visse R., Nagase H.: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res., 2003; 92: 827-839
81. Wang H., Keiser J.A.: Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells. Circ. Res., 1998; 83: 832-840
82. Wang L., Luo J., He S.: Induction of MMP-9 release from human dermal fibroblasts by thrombin: involvement of JAK/STAT3 signaling pathway in MMP-9 release. BMC Cell, Biol., 2007; 8: 14
83. Wang Z., Juttermann R., Soloway P.D.: TIMP-2 is required for efficient activation of proMMP-2 in vivo. J. Biol. Chem., 2000; 275: 26411-26415
84. Westermarck J., Kähäri V.: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J., 1999; 13: 781-792
85. Yan X., Tezel G., Wax M.B., Edward D.P.: Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch. Ophthalmol., 2000; 118: 666-673
86. Zahner G., Harendza S., Müller E., Wolf G., Thaiss F., Stahl R.: Prostaglandin E2 stimulates expression of matrix metalloproteinase 2 in cultured rat mesangial cells. Kidney Int., 1997; 51: 1116-1123
87. Zhu P., Ding J., Zhou J., Dong W., Fan C, Chen Z.: Expression of CD147 on monocytes/macrophages in rheumatoid arthritis: its potential role in monocyte accumulation and matrix metalloproteinase production. Arthritis Res. Ther., 2005; 7: 1023-1033
88. Zucker S., Hymowitz M., Rollo E.E., Mann R., Conner C.E., Cao J., Foda H.D., Tompkins D.C., Toole B.P.: Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am. J. Pathol., 2001; 158: 1921-1928
89. Zebrowska A., Bogdañska M., Waszczykowska E.: Metaloproteinazy i adamalizyny w patomechanizmie pemfigoidu. PDiA, 2005; 22: 283-287